R Squared Ltd Takes $272,000 Position in OrthoPediatrics Corp. $KIDS

R Squared Ltd acquired a new stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 12,682 shares of the company’s stock, valued at approximately $272,000. R Squared Ltd owned approximately 0.05% of OrthoPediatrics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its holdings in shares of OrthoPediatrics by 112.3% in the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock worth $4,937,000 after buying an additional 106,041 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in shares of OrthoPediatrics by 116.5% in the second quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock worth $7,173,000 after buying an additional 179,733 shares during the period. Invesco Ltd. boosted its holdings in shares of OrthoPediatrics by 12.1% in the first quarter. Invesco Ltd. now owns 18,349 shares of the company’s stock worth $452,000 after buying an additional 1,986 shares during the period. Triodos Investment Management BV boosted its holdings in shares of OrthoPediatrics by 25.0% in the second quarter. Triodos Investment Management BV now owns 112,500 shares of the company’s stock worth $2,415,000 after buying an additional 22,500 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of OrthoPediatrics by 16.1% in the first quarter. American Century Companies Inc. now owns 30,658 shares of the company’s stock worth $755,000 after buying an additional 4,248 shares during the period. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a report on Saturday. BTIG Research reduced their price target on shares of OrthoPediatrics from $39.00 to $23.00 and set a “buy” rating for the company in a research report on Friday, October 10th. Citigroup reissued an “outperform” rating on shares of OrthoPediatrics in a research report on Friday, October 10th. Wall Street Zen lowered shares of OrthoPediatrics from a “hold” rating to a “sell” rating in a research report on Saturday, October 11th. Finally, Lake Street Capital reduced their price target on shares of OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, October 10th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, OrthoPediatrics currently has an average rating of “Moderate Buy” and an average price target of $26.29.

OrthoPediatrics Price Performance

Shares of KIDS opened at $17.03 on Friday. The firm has a market cap of $426.94 million, a PE ratio of -9.51 and a beta of 1.02. The firm’s 50 day moving average price is $19.13 and its 200 day moving average price is $20.59. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.43 and a current ratio of 6.66. OrthoPediatrics Corp. has a twelve month low of $15.28 and a twelve month high of $32.00.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Monday, January 9th. The company reported ($0.15) earnings per share for the quarter. The business had revenue of $25.08 million for the quarter. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. As a group, research analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other OrthoPediatrics news, CFO Fred Hite acquired 5,076 shares of the business’s stock in a transaction that occurred on Thursday, August 21st. The shares were purchased at an average price of $19.41 per share, with a total value of $98,525.16. Following the completion of the transaction, the chief financial officer owned 213,065 shares in the company, valued at $4,135,591.65. The trade was a 2.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 32.70% of the company’s stock.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.